Women's imaging vendor Hologic swung to a net loss for the company's second quarter (end-March 24), despite 7% growth in the firm's revenues for the period. Separately, Hologic announced a $3.7 billion deal to buy diagnostics firm Gen-Probe.
For the quarter, Hologic posted revenues of $471.2 million, up 7.4% compared to revenues of $438.7 million in the same period the year before. Revenues in the company's Breast Health segment increased to $218.6 million, up 6.2% compared to $205.9 million in the corresponding quarter last year.
The company's net loss for the period was $40.3 million, compared with net income of $82.4 in the second quarter of 2011.
On April 30, Hologic announced a deal worth $3.7 billion to acquire Gen-Probe, a developer of molecular diagnostics products and services. Gen-Probe makes products such as blood tests for detecting sexually transmitted diseases and the West Nile virus.
Hologic expects the deal to be accretive to earnings, with the combined company having annual revenues of $2.4 billion. The acquisition is expected to close in the second half of 2012.
